- Home
- MOLN vs UCL Comparison
MOLN vs UCL Comparison
Compare MOLN & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- UCL
- Stock Information
- Founded
- MOLN 2004
- UCL 2014
- Country
- MOLN Switzerland
- UCL Hong Kong
- Employees
- MOLN N/A
- UCL N/A
- Industry
- MOLN
- UCL Telecommunications Equipment
- Sector
- MOLN
- UCL Consumer Discretionary
- Exchange
- MOLN Nasdaq
- UCL Nasdaq
- Market Cap
- MOLN 142.6M
- UCL 144.5M
- IPO Year
- MOLN 2021
- UCL 2020
- Fundamental
- Price
- MOLN $3.71
- UCL $2.30
- Analyst Decision
- MOLN Hold
- UCL
- Analyst Count
- MOLN 1
- UCL 0
- Target Price
- MOLN $4.00
- UCL N/A
- AVG Volume (30 Days)
- MOLN 2.3K
- UCL 60.3K
- Earning Date
- MOLN 11-05-2025
- UCL 11-25-2025
- Dividend Yield
- MOLN N/A
- UCL N/A
- EPS Growth
- MOLN N/A
- UCL N/A
- EPS
- MOLN N/A
- UCL 0.02
- Revenue
- MOLN $856,302.00
- UCL $89,277,000.00
- Revenue This Year
- MOLN N/A
- UCL N/A
- Revenue Next Year
- MOLN $1,000.00
- UCL $20.86
- P/E Ratio
- MOLN N/A
- UCL $95.73
- Revenue Growth
- MOLN N/A
- UCL 3.72
- 52 Week Low
- MOLN $3.36
- UCL $0.80
- 52 Week High
- MOLN $7.60
- UCL $4.19
- Technical
- Relative Strength Index (RSI)
- MOLN 50.18
- UCL 40.22
- Support Level
- MOLN $3.68
- UCL $2.10
- Resistance Level
- MOLN $3.85
- UCL $2.44
- Average True Range (ATR)
- MOLN 0.09
- UCL 0.15
- MACD
- MOLN 0.00
- UCL -0.02
- Stochastic Oscillator
- MOLN 50.00
- UCL 28.81
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.